Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23095143 | 0.86 | PNMT (0.42) | PNMTLMNASOS1TSHRKDM4E | |
| SCHEMBL18826868 | 0.86 | PNMT (0.42) | PNMTLMNASOS1TSHRKDM4E | |
| SCHEMBL24568964 | 0.86 | PNMT (0.44) | PNMTSLC6A2SLC6A3 | |
| SCHEMBL19772459 | 0.83 | PNMT (0.63) | PNMTTSHRMEN1KMT2ASLC6A2 | |
| SCHEMBL6126362 | 0.83 | PNMT (0.48) | PNMTLMNASOS1TSHRKDM4E | |
| SCHEMBL13165986 | 0.83 | PNMT (0.63) | PNMTTSHRMEN1KMT2ASLC6A2 | |
| SCHEMBL13165985 | 0.83 | PNMT (0.63) | PNMTTSHRMEN1KMT2ASLC6A2 | |
| SCHEMBL14463122 | 0.83 | ALDH1A1 (0.38) | LMNAKDM4EMEN1KMT2ASLC6A2 | |
| SCHEMBL15178130 | 0.82 | TSHR (0.41) | PNMTLMNASOS1TSHRKDM4E | |
| SCHEMBL28747785 | 0.80 | PNMT (0.46) | PNMTLMNASOS1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | VANDERBILT UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | NRAS, KRAS, MAVS | PNMT 3692/4885LMNA 3082/4885SOS1 353/4885 |
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | NRAS, KRAS, MAVS | PNMT 3692/4885LMNA 3082/4885SOS1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.